CIK 0001346830
- Non-accelerated filer
- Smaller reporting company
Tvardi Therapeutics, Inc.
Sign in to watch- Ticker
- TVRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 713-489-8654
- Business address
- 3 SUGAR CREEK CTR. BLVD., STE 525, SUGAR LAND, TX, 77478
- Former names
- Cara Therapeutics, Inc., Cara Therapeutics Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-09 | Shiff Susan Ph.D. Director | Grant or award · Stock Option (right to buy) | +6,000 | 6,000 | ||
| 2026-06-09 | HALL WALLACE L JR Director | Grant or award · Stock Option (right to buy) | +6,000 | 6,000 | ||
| 2026-06-09 | Smith Cynthia Director | Grant or award · Stock Option (right to buy) | +6,000 | 6,000 | ||
| 2026-06-09 | Shah Sujal Director | Grant or award · Stock Option (right to buy) | +6,000 | 6,000 | ||
| 2026-06-09 | WYZGA MICHAEL S Director | Grant or award · Stock Option (right to buy) | +6,000 | 6,000 | ||
| 2026-01-29 | Conn Avi Daniel Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2026-01-29 | O'Brien Stephen Paul Principal Accounting Officer | Grant or award · Employee Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2026-01-29 | Alibhai Imran Nizamudin Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +115,000 | 115,000 | ||
| 2026-01-29 | Kauh John Saewook M.D. Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2025-12-16 | Conn Avi Daniel Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2025-12-16 | O'Brien Stephen Paul Principal Accounting Officer | Grant or award · Employee Stock Option (right to buy) | +4,000 | 4,000 | ||
| 2025-12-16 | Alibhai Imran Nizamudin Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +47,500 | 47,500 | ||
| 2025-12-16 | Kauh John Saewook M.D. Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +17,500 | 17,500 | ||
| 2025-07-07 | Tweardy Samuel David 10% owner | Other disposition | −315,658 | 0 | ||
| 2025-07-07 | Tweardy Samuel David 10% owner | Other disposition | −315,658 | 0 | ||
| 2025-04-17 | Larson Jeffrey Leroy SVP, Research & Development | Grant or award · Employee Stock Option (right to buy) | +10,820 | 10,820 | ||
| 2025-04-17 | O'Brien Stephen Paul Principal Accounting Officer | Grant or award · Employee Stock Option (right to buy) | +7,213 | 7,213 | ||
| 2025-04-17 | Chen Yixin VP, Chem, Mfg and Ctrls | Grant or award · Employee Stock Option (right to buy) | +7,213 | 7,213 | ||
| 2025-04-17 | Conn Avi Daniel Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +43,547 | 43,547 | ||
| 2025-04-17 | Kauh John Saewook M.D. Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +36,210 | 36,210 |
Page 1 of 7 · 123 trades